Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Market Cap	5.78B +1.5%
Revenue (ttm)	3.35B +9.9%
Net Income	345.57M +3.8%
EPS	1.81 +3.4%
Shares Out	190.20M
PE Ratio	16.80
Forward PE	n/a
Dividend	0.95 (3.11%)
Ex-Dividend Date	Jul 11, 2025

Volume	4,000
Average Volume	225,851
Open	30.40
Previous Close	30.40
Day's Range	30.35 - 30.40
52-Week Range	25.95 - 32.60
Beta	0.15
RSI	39.20
Earnings Date	Mar 20, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1977
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1734

Financial Performance

In 2024, Sinphar Pharmaceutical's revenue was 3.15 billion, an increase of 6.33% compared to the previous year's 2.96 billion. Earnings were 304.71 million, a decrease of -18.78%.